Gilead Working 24/7 To Fix Manufacturing Problems In HIV “Complete Response” Letters
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first quarter earnings call, Gilead says it’s been working around the clock to address manufacturing issues that blocked FDA approval of two individual drugs in the approved Stribild HIV combination pill, problems that also affect other marketed drugs. But rising star HCV drug sofosbuvir won’t be affected, company says.